After riding high for much of the pandemic, mRNA vaccine pioneers came down to earth in 2022. By mid-June, the share prices of both Massachusetts-based Moderna and Germany’s BioNTech had more than halved. But investors’ excitement was rekindled a few weeks ago when Moderna and partner Merck published a promising set of melanoma trial results. After five decades of failed attempts, cancer vaccines are set for a breakthrough.
在疫情期間大部分時間內持續上漲後，mRNA疫苗的先驅企業股票在2022年回到了地面上。截至去年6月中旬，總部位於麻薩諸塞州的莫德納(Moderna)和德國的BioNTech的股價都下跌了一半以上。但幾周前，莫德納及其合作伙伴默克公司(Merck)公佈了一組很有前景的黑色素瘤試驗疫苗，投資者的興奮之情重新燃起。在經歷了50年的失敗嘗試後，癌症疫苗即將取得突破。
您已閱讀23%（607字），剩餘77%（2005字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。